相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer
Shaorong Deng et al.
CANCER LETTERS (2019)
CXCL11 promotes self-renewal and tumorigenicity of α2δ1+ liver tumor-initiating cells through CXCR3/ERK1/2 signaling
Yuan Zhang et al.
CANCER LETTERS (2019)
Epithelial mesenchymal transition induced by the CXCL9/CXCR3 axis through AKT activation promotes invasion and metastasis in tongue squamous cell carcinoma
Ziliang Li et al.
ONCOLOGY REPORTS (2018)
Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
Soledad Urra et al.
ONCOTARGET (2018)
Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists
Martyna Szpakowska et al.
BIOCHEMICAL PHARMACOLOGY (2018)
CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
Chenlu Zhang et al.
BMC CANCER (2018)
Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3
Martyna Szpakowska et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands
Mieke Metzemaekers et al.
FRONTIERS IN IMMUNOLOGY (2018)
Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition
Yu Jie Gao et al.
ONCOTARGETS AND THERAPY (2018)
The Inflammatory CXC Chemokines, GROhigh, IP-10low, and MIGlow, in Tumor Microenvironment Can Be Used as New Indicators for Non-small Cell Lung Cancer Progression
Ya Cao et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Robert Sackstein et al.
LABORATORY INVESTIGATION (2017)
C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways
Jeffrey S. Smith et al.
MOLECULAR PHARMACOLOGY (2017)
Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner
Takouhie Mgrditchian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells
Theresa Relation et al.
STEM CELLS (2017)
Role of tumor microenvironment in tumorigenesis
Maonan Wang et al.
JOURNAL OF CANCER (2017)
CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients
C. Windmueller et al.
ONCOGENESIS (2017)
Oligomerization State of CXCL4 Chemokines Regulates G Protein-Coupled Receptor Activation
Ya-Ping Chen et al.
ACS CHEMICAL BIOLOGY (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Microenvironmental regulation of tumour angiogenesis
Michele de Palma et al.
NATURE REVIEWS CANCER (2017)
CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma
Yusuke Sato et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets
Nathan Karin et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Small Molecule CXCR3 Antagonists
Stephen P. Andrews et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Epidermotropic B-Cell Lymphoma: A Unique Subset of CXCR3-Positive Marginal Zone Lymphoma
Cynthia M. Magro et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2016)
New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model
Andrew B. Kleist et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7
Martyna Szpakowska et al.
BIOCHEMICAL PHARMACOLOGY (2016)
The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients
Zhenqian Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
Holger Bronger et al.
BRITISH JOURNAL OF CANCER (2016)
Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer
Cathy Quemener et al.
CANCER RESEARCH (2016)
CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation
Chang Xian Li et al.
JOURNAL OF HEPATOLOGY (2016)
Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors
Zinal S. Chheda et al.
JOURNAL OF IMMUNOLOGY (2016)
Atypical chemokine receptors in cancer: friends or foes?
Matteo Massara et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
PF4 Promotes Platelet Production and Lung Cancer Growth
Ferdinando Pucci et al.
CELL REPORTS (2016)
CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer
Ming Bai et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways
Yamina A. Berchiche et al.
MOLECULAR PHARMACOLOGY (2016)
Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome
S. C. Wightman et al.
BRITISH JOURNAL OF CANCER (2015)
CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity
Yang Zhang et al.
CANCER BIOLOGY & THERAPY (2015)
CXCR3 ligands in disease and therapy
Katrien Van Raemdonck et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
CXCR3 Polymorphism and Expression Associate with Spontaneous Preterm Birth
Minna K. Karjalainen et al.
JOURNAL OF IMMUNOLOGY (2015)
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
Rosa Barreira da Silva et al.
NATURE IMMUNOLOGY (2015)
Differential regulation of pericyte function by the CXC receptor 3
Richard J. Bodnar et al.
WOUND REPAIR AND REGENERATION (2015)
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
M. E. Mikucki et al.
NATURE COMMUNICATIONS (2015)
Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration
Timothy J. Zumwalt et al.
ONCOTARGET (2015)
CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti-tumor immunity
Guiquan Zhu et al.
ONCOTARGET (2015)
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Muhammad A. Mir et al.
BLOOD (2015)
Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis
Yanchun Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype
Yi Pu et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Jason W. Griffith et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer
Kathrin Rupertus et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers
Christelle Freitas et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model
Steve Oghumu et al.
IMMUNOLOGY (2014)
A Novel CXCR3-B Chemokine Receptor-induced Growth-inhibitory Signal in Cancer Cells Is Mediated through the Regulation of Bach-1 Protein and Nrf2 Protein Nuclear Translocation
Murugabaskar Balan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis (Publication with Expression of Concern. See vol. 128, pg. 1200, 2018) (Publication with Expression of Concern. See vol. 127, pg. 3913, 2017)
Yaniv Zohar et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
CXCR3, a double-edged sword in tumor progression and angiogenesis
Clotilde Billottet et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Anna Marie Mulligan et al.
CLINICAL CANCER RESEARCH (2013)
PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4+ T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes
Kristen E. Pauken et al.
DIABETES (2013)
The role of CXCR3 and CXCR4 in colorectal cancer metastasis
Teppei Murakami et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation
Anne O. Watts et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3
D. J. Scholten et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response
Katarzyna Franciszkiewicz et al.
CANCER RESEARCH (2012)
CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
Nassima Redjimi et al.
CANCER RESEARCH (2012)
Overview of the mechanisms regulating chemokine activity and availability
Anneleen Mortier et al.
IMMUNOLOGY LETTERS (2012)
Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer
Yuji Toiyama et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
The tumor microenvironment at a glance
Frances R. Balkwill et al.
JOURNAL OF CELL SCIENCE (2012)
Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion
Qian Wu et al.
MOLECULAR CANCER (2012)
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer
Holger Bronger et al.
BREAST CANCER RESEARCH (2012)
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3
Sofie Struyf et al.
BLOOD (2011)
CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells
S. Amatschek et al.
BRITISH JOURNAL OF CANCER (2011)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
CXCR3 Enhances a T-Cell-Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis
Ashley E. Winkler et al.
CANCER RESEARCH (2011)
Chemokine receptor CXCR3 promotes growth of glioma
Che Liu et al.
CARCINOGENESIS (2011)
Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis
Mitsuko Furuya et al.
GYNECOLOGIC ONCOLOGY (2011)
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes
Anna Korniejewska et al.
IMMUNOLOGY (2011)
CXCR3 ligands: redundant, collaborative and antagonistic functions
Joanna R. Groom et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
CXCR3-B Can Mediate Growth-inhibitory Signals in Human Renal Cancer Cells by Down-regulating the Expression of Heme Oxygenase-1
Dipak Datta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Roles for Growth Factors in Cancer Progression
Esther Witsch et al.
PHYSIOLOGY (2010)
CXCL10 Can Inhibit Endothelial Cell Proliferation Independently of CXCR3
Gabriele S. V. Campanella et al.
PLOS ONE (2010)
Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3(+) T cells in lymphocyte-rich gastric carcinoma
H. Ohtani et al.
JOURNAL OF PATHOLOGY (2009)
CXCR3-B Expression Correlates With Tumor Necrosis Extension in Renal Cell Carcinoma
Mauro Gacci et al.
JOURNAL OF UROLOGY (2009)
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
Xinrong Ma et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Marco Wendel et al.
CANCER RESEARCH (2008)
The role of CD26/dipeptidyl peptidase IV in cancer
Pamela A. Havre et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3
Anja Mueller et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation
Seema V. Maru et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Calcineurin Inhibitors Modulate CXCR3 Splice Variant Expression and Mediate Renal Cancer Progression
Dipak Datta et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma
Tobias Klatte et al.
JOURNAL OF UROLOGY (2008)
How chemokines invite leukocytes to dance
Marcus Thelen et al.
NATURE IMMUNOLOGY (2008)
Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay
L. A. Jopling et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7
Frederic Sierro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes
K. Kawada et al.
ONCOGENE (2007)
Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis
Sofie Struyf et al.
CANCER RESEARCH (2007)
CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors
C. Monteagudo et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy
Karen L. Reckamp et al.
JOURNAL OF IMMUNOTHERAPY (2007)
CXCL10 promotes invasion-related properties in human colorectal carcinoma cells
Adi Zipin-Roitman et al.
CANCER RESEARCH (2007)
Inhibition of Gαi2 activation by Gαi3 in CXCR3-mediated signaling
Brian D. Thompson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
CXC chemokine ligand 9/monokine induced by IFN-γ production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors
Anton V. Gorbachev et al.
JOURNAL OF IMMUNOLOGY (2007)
Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer
Dipak Datta et al.
CANCER RESEARCH (2006)
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
Jennifer M. Burns et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis
JD Pan et al.
JOURNAL OF IMMUNOLOGY (2006)
CXC chemokines in angiogenesis
RM Strieter et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH cytokine production
P Romagnani et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis
PJ Hensbergen et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist
CE Heise et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells
SG Kelsen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease
IM Mullins et al.
CANCER RESEARCH (2004)
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes
K Kawada et al.
CANCER RESEARCH (2004)
Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis
S Struyf et al.
CIRCULATION RESEARCH (2004)
Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-γ in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids
P Proost et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
CXCR3-mediated chernotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase
MJ Smit et al.
BLOOD (2003)
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4
L Lasagni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies
C Blanpain et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
CXCR3 internalization following T cell-endothelial cell contact:: Preferential role of IFN-Inducible T cell α chemoattractant (CXCL11)
A Sauty et al.
JOURNAL OF IMMUNOLOGY (2001)
Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties
P Proost et al.
BLOOD (2001)
Antigenically distinct conformations of CXCR4
F Baribaud et al.
JOURNAL OF VIROLOGY (2001)
Signal transduction by the chemokine receptor CXCR3 - Activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes
A Bonacchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
